{"nctId":"NCT00601523","briefTitle":"Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).","startDateStruct":{"date":"2008-01"},"conditions":["Parkinson Disease"],"count":511,"armGroups":[{"label":"Pramipexole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pramipexole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Pramipexole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Completion of the double-blind trial 248.524 or 248.636\n2. Male or female patient with early idiopathic Parkinson´s disease (PD), and with a Modified Hoehn and Yahr stage of I to III.\n3. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n4. Signed informed consent obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) guidelines and local legislation).\n\nExclusion criteria:\n\n1. Patients prematurely withdrawn from the double-blind trials 248.524 or 248.636.\n2. Atypical parkinsonian syndromes due to drugs,metabolic disorders, encephalitis or degenerative diseases.\n3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.4.History of psychosis, except history of drug induced hallucinations.\n\n5\\. Clinically significant electrocardiogram (ECG) abnormalities at baseline. 6.Clinically significant hypotension 7.Malignant melanoma or history of previously treated malignant melanoma. 8.Any other clinically significant disease, that could put the patient at risk or could prevent compliance or completion of the study. 9. Pregnancy or breast-feeding.\n\n10\\. Sexually active female of childbearing potential not using a medically approved method of birth control for at least one month prior to the baseline and throughout the study.11 Serum levels of aspartate aminotransferase (AST) (SGOT), alanine aminotransferase (ALT) (SGPT), alkaline phosphatase or bilirubin \\> 2 upper limit of normal (ULN) at baseline 12. Patients with a creatinine clearance \\< 50 mL/min (estimated by the Cockcroft and Gault formula). 13. Motor complications under levodopa therapy (e.g. on-off phenomena, dyskinesia) at baseline.\n\n14\\. Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit. 15.Any of the following drugs within 4 weeks prior to baseline: methylphenidate, cinnarizine, amphetamines. 16. Flunarizine within 3 months prior to baseline.\n\n17\\. Known hypersensitivity to pramipexole or its excipients. 18. Drug abuse (including alcohol), according to investigator´s judgement, within 2 years prior to baseline.\n\n19\\. Participation in investigational drug studies other than trials 248.524 and 248.636 or use of other investigational drug within one month or five times the half-life of the investigational drug prior to baseline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline","description":"UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"9.5"},{"groupId":"OG001","value":"1.5","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)","description":"A response means an improvement of \\>=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"UPDRS I Total Score: Change From OL Baseline","description":"UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"UPDRS II Total Score: Change From OL Baseline","description":"UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"3.2"},{"groupId":"OG001","value":"0.6","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"UPDRS III Total Score: Change From OL Baseline","description":"UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"7.2"},{"groupId":"OG001","value":"0.9","spread":"5.6"}]}]}]},{"type":"SECONDARY","title":"Response in Clinical Global Impression of Improvement (CGI-I)","description":"Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least \"much improved\" were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Response in Patient Global Impression of Improvement (PGI-I)","description":"Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least \"much better\" were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline","description":"PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"12.5"},{"groupId":"OG001","value":"2.2","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Introducing L-Dopa Medication in OL Trial","description":"Number of patients requiring Levodopa supplementation during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"L-Dopa Dose: Change From OL Baseline","description":"Change from open-label baseline in Levodopa dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients","description":"Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events","description":"The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Preference Regarding Treatment Dosing","description":"Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Rating of Convenience of Treatment Dosing","description":"Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":368},"commonTop":["Somnolence","Oedema peripheral","Back pain","Nausea","Nasopharyngitis"]}}}